Dr Reddy's, India's third-largest listed pharmaceutical company by market capitalisation, posted a steady performance for the December quarter. Barring Europe, which saw a decline, most key markets posted YoY growth in the quarter, leading to 8 per cent growth in consolidated revenues.
Among the top performers were the emerging markets, which reported a 20 per cent jump; the proprietary business gained 37 per cent. Within emerging markets, the rest of the world segment saw sharp 46 per cent growth aided by product launches and higher sales volumes for the base business. The emerging markets business of Dr Reddy’s is the second-largest